Scientists probe hidden immune cells behind hepatitis b vaccine success
NCT ID NCT06876467
First seen Apr 25, 2026 · Last updated Jun 22, 2026 · Updated 9 times
Summary
This study looks at how T cells—a type of immune cell—respond after hepatitis B vaccination in healthy adults. Researchers want to understand why some people maintain protection longer and how these cells might help control the virus. About 115 participants will provide blood samples 5 to 10 weeks after vaccination for detailed analysis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE RESPONSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Saint Louis AP-HP
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hepatitis B vaccine
What this could lead to
If successful, this study could reveal how T cells contribute to long-term protection after hepatitis B vaccination, potentially improving future vaccines.
What could go wrong
This is an observational study with only 115 participants, so results may not apply to everyone. It does not test a new treatment or vaccine.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.